{"product_id":"heart-in-diabetes-9th-annual-heart-in-diabetes-conference-2025","title":"Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: cardiologists, endocrinologists, and nephrologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eCourse Date: 2025\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eEvaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy.\u003c\/p\u003e\n\u003cp\u003eImplement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes.\u003c\/p\u003e\n\u003cp\u003eAnalyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health.\u003c\/p\u003e\n\u003cp\u003eAssess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice.\u003c\/p\u003e\n\u003cp\u003eApply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eDay 1 01 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment\u003c\/p\u003e\n\u003cp\u003eDay 1 02 Management of Chronic Kidney Disease With or Without Albuminuria\u003c\/p\u003e\n\u003cp\u003eDay 1 03 Emerging Approaches to the Treatment of Resistant Hypertension\u003c\/p\u003e\n\u003cp\u003eDay 1 04 Case Presentation – Treatment Resistant Hypertension\u003c\/p\u003e\n\u003cp\u003eDay 1 05 Cortisol – Impact on Endocrinology \u0026amp; Metabolism\u003c\/p\u003e\n\u003cp\u003eDay 1 06 Cortisol’s Impact on the Kidney-BP-Bone\u003c\/p\u003e\n\u003cp\u003eDay 1 07 Cardiovascular Implications of Hypercortisolism\u003c\/p\u003e\n\u003cp\u003eDay 1 08 Panel Discussion and Q\u0026amp;A – Cortisol \u0026amp; Cardiorenalmetabolic Diseases\u003c\/p\u003e\n\u003cp\u003eDay 1 09 MASLD and MASH – Pathophysiology, Diagnosis and Management\u003c\/p\u003e\n\u003cp\u003eDay 1 10 Sleep Health – Implications for Obesity and Diabetes Risk\u003c\/p\u003e\n\u003cp\u003eDay 1 11 Sleep and Cardiovascular Risk\u003c\/p\u003e\n\u003cp\u003eDay 1 12 Panel Discussion and Q\u0026amp;A – Sleep Disorders in Cardiometabolism\u003c\/p\u003e\n\u003cp\u003eDay 1 13 Prediabetes – What’s a Clinician to Do\u003c\/p\u003e\n\u003cp\u003eDay 1 14 Unraveling the Connection – Diabetes and Dementia\u003c\/p\u003e\n\u003cp\u003eDay 1 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease\u003c\/p\u003e\n\u003cp\u003eDay 1 16 Diabetes and Cardiovascular Disease in Older Adults\u003c\/p\u003e\n\u003cp\u003eDay 1 17 Panel Discussion and Q\u0026amp;A – Diabetes Comorbidities\u003c\/p\u003e\n\u003cp\u003eDay 1 18 Implementing Guideline-Directed Medical Therapy – Stakeholder-Identified Barriers and Facilitators\u003c\/p\u003e\n\u003cp\u003eDay 1 19 Population Health Approaches to Accelerate the Prevention of CVD – Moving from Action to Impact\u003c\/p\u003e\n\u003cp\u003eDay 1 20 Panel Discussion and Q\u0026amp;A – Implementation Science in Practice\u003c\/p\u003e\n\u003cp\u003eDay 1 21 Dyslipidemia in Women Across a Lifetime Approach to Management\u003c\/p\u003e\n\u003cp\u003eDay 1 22 Sex Hormones and Anthropometric Measures \u0026amp; Heart Failure Risk in Women\u003c\/p\u003e\n\u003cp\u003eDay 1 23 Panel Discussion and Q\u0026amp;A – Women’s Health\u003c\/p\u003e\n\u003cp\u003eDay 1 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis\u003c\/p\u003e\n\u003cp\u003eDay 1 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibro…\u003c\/p\u003e\n\u003cp\u003eDay 1 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease\u003c\/p\u003e\n\u003cp\u003eDay 1 28 Panel Discussion and Q\u0026amp;A – Circulation\u003c\/p\u003e\n\u003cp\u003eDay 2 01 Current Trends in Epidemiology of Heart Failure – USA\u003c\/p\u003e\n\u003cp\u003eDay 2 02 Diabetic Cardiomyopathy – Mechanisms and Future Directions\u003c\/p\u003e\n\u003cp\u003eDay 2 03 Bromocriptine in the Treatment of Peripartum Cardiomyopathy – Is It Ready for Prime Time\u003c\/p\u003e\n\u003cp\u003eDay 2 04 Proper Medical Management of HFpEF in 2025\u003c\/p\u003e\n\u003cp\u003eDay 2 05 Panel Discussion and Q\u0026amp;A – Heart Failure – The Now \u0026amp; The New\u003c\/p\u003e\n\u003cp\u003eDay 2 06 GLP1-RA, Obesity \u0026amp; Diabetes – Mechanisms of Cardiovascular Protection\u003c\/p\u003e\n\u003cp\u003eDay 2 07 Cardio-Kidney Protection With Incretin Therapies\u003c\/p\u003e\n\u003cp\u003eDay 2 08 Incretins – Today and Tomorrow\u003c\/p\u003e\n\u003cp\u003eDay 2 09 Panel Discussion and Q\u0026amp;A – Current \u0026amp; Future Role of Incretin Therapy\u003c\/p\u003e\n\u003cp\u003eDay 2 10 Diabetes and Cardiovascular Disease – The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications\u003c\/p\u003e\n\u003cp\u003eDay 2 11 My Personal Journey to HoFH Diagnosis\u003c\/p\u003e\n\u003cp\u003eDay 2 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders\u003c\/p\u003e\n\u003cp\u003eDay 2 13 CETPi – Where Might They Fit Into Clinical Practice\u003c\/p\u003e\n\u003cp\u003eDay 2 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets\u003c\/p\u003e\n\u003cp\u003eDay 2 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists\u003c\/p\u003e\n\u003cp\u003eDay 2 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases\u003c\/p\u003e\n\u003cp\u003eDay 2 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes\u003c\/p\u003e\n\u003cp\u003eDay 2 18 Finerenone Across the Stages of Heart Failure – From Prevention to Treatment\u003c\/p\u003e\n\u003cp\u003eDay 2 19 Panel Discussion and Q\u0026amp;A – Cardio-Renal Protection in CKM Diseases\u003c\/p\u003e\n\u003cp\u003eDay 2 20 Digital Health Technologies for Cardiometabolic Disease \u0026amp; Diabetes\u003c\/p\u003e\n\u003cp\u003eDay 2 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes – The Look AHEAD Cardiac…\u003c\/p\u003e\n\u003cp\u003eDay 2 24 Panel Discussion and Q\u0026amp;A – JACC\u003c\/p\u003e\n\u003cp\u003eDay 2 25 Technology in the Management of Diabetes – Addressing Its Role in Comorbidities\u003c\/p\u003e\n\u003cp\u003eDay 2 26 SGLT2 Inhibitors – Reconsidering, Repurposing, Reimagining\u003c\/p\u003e\n\u003cp\u003eDay 2 27 Panel Discussion and Q\u0026amp;A – Diabetes Management \u0026amp; Technology\u003c\/p\u003e\n\u003cp\u003eDay 3 01 Management of Complex Cases – Obesity and Heart Failure\u003c\/p\u003e\n\u003cp\u003eDay 3 02 The Edema Dilemma – A Case of Diabetes Mellitus, Heart Failure With Preserved Ejection Fraction, Obesity, Chronic Kidne…\u003c\/p\u003e\n\u003cp\u003eDay 3 03 CRM Management of Complex Cases\u003c\/p\u003e\n\u003cp\u003eDay 3 04 The Lancet Commission on Obesity\u003c\/p\u003e\n\u003cp\u003eDay 3 05 Obesity – Role of Medical Management\u003c\/p\u003e\n\u003cp\u003eDay 3 06 Management of Obesity Addressing Lean Mass Preservation\u003c\/p\u003e\n\u003cp\u003eDay 3 07 Panel Discussion and Q\u0026amp;A – Obesity\u003c\/p\u003e\n\u003cp\u003eDay 3 08 Do ACEiARB Still Have a Role in the Era of SGLT2, MRA and GLP1A\u003c\/p\u003e\n\u003cp\u003eDay 3 09 The Role of Diastolic \u0026amp; Pulse Pressure in CKD \u0026amp; CVD – Management Considerations\u003c\/p\u003e\n\u003cp\u003eDay 3 10 Aldosterone – The Forgotten Hormone in Hypertension\u003c\/p\u003e\n\u003cp\u003eDay 3 11 Panel Discussion and Q\u0026amp;A – The Kidney and Hypertension\u003c\/p\u003e\n\u003cp\u003eDay 3 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease\u003c\/p\u003e\n\u003cp\u003eDay 3 13 The Latest Heart Disease \u0026amp; Stroke Statistics – US \u0026amp; Global Data from the American Heart Association\u003c\/p\u003e\n\u003cp\u003eDay 3 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal \u0026amp; Metabolic Medicine Patient\u003c\/p\u003e\n\u003cp\u003eDay 3 15 Serum Lipoproteins \u0026amp; Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors\u003c\/p\u003e\n\u003cp\u003eDay 3 16 Cardiovascular Outcome Trials Update\u003c\/p\u003e\n\u003cp\u003eDay 3 17 Panel Discussion and Q\u0026amp;A – ASCVD\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405808980164,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Heart-in-Diabetes-9th-Annual-Heart-in-Diabetes-Conference-2025.jpg?v=1784216511","url":"https:\/\/medicalcoursespro.com\/products\/heart-in-diabetes-9th-annual-heart-in-diabetes-conference-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}